Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley R Riddell

Showing results (61-70 of 177) with videos related to

Pageof 18
Sort By:
Cancer Immunology Research|September 13, 2014
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activityMichael Hudecek, Daniel Sommermeyer, Paula L Kosasih, et al.
Journal for Immunotherapy of Cancer|December 10, 2020
Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumabJoshua R Veatch, Naina Singhi, Brenda Jesernig, et al.
Nature Reviews. Clinical Oncology|November 23, 2022
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumoursChristian L Flugel, Robbie G Majzner, Giedre Krenciute, et al.
Frontiers in Immunology|January 26, 2024
A chimeric antigen receptor-based cellular safeguard mechanism for selective <i>in vivo</i> depletion of engineered T cellsMortimer Svec, Sarah Dötsch, Linda Warmuth, et al.
Human Gene Therapy|December 21, 2006
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophyZejing Wang, James M Allen, Stanley R Riddell, et al.
Blood|June 8, 2013
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemiaMargaret L Green, Wendy M Leisenring, Hu Xie, et al.
Cancer Immunology Research|October 31, 2014
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cellsCarolina Berger, Daniel Sommermeyer, Michael Hudecek, et al.
Blood|July 5, 2003
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivationMorgan Hakki, Stanley R Riddell, Jan Storek, et al.
The Journal of Experimental Medicine|March 18, 2009
Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupusZhenpeng Dai, Cameron J Turtle, Garrett C Booth, et al.
Cancer Journal (Sudbury, Mass.)|March 27, 2014
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset compositionStanley R Riddell, Daniel Sommermeyer, Carolina Berger, et al.
Pageof 18

Showing results (61-70 of 177) with videos related to

Sort By:
Pageof 18
Cancer Immunology Research|September 13, 2014
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activityMichael Hudecek, Daniel Sommermeyer, Paula L Kosasih, et al.
Journal for Immunotherapy of Cancer|December 10, 2020
Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumabJoshua R Veatch, Naina Singhi, Brenda Jesernig, et al.
Nature Reviews. Clinical Oncology|November 23, 2022
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumoursChristian L Flugel, Robbie G Majzner, Giedre Krenciute, et al.
Frontiers in Immunology|January 26, 2024
A chimeric antigen receptor-based cellular safeguard mechanism for selective <i>in vivo</i> depletion of engineered T cellsMortimer Svec, Sarah Dötsch, Linda Warmuth, et al.
Human Gene Therapy|December 21, 2006
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophyZejing Wang, James M Allen, Stanley R Riddell, et al.
Blood|June 8, 2013
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemiaMargaret L Green, Wendy M Leisenring, Hu Xie, et al.
Cancer Immunology Research|October 31, 2014
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cellsCarolina Berger, Daniel Sommermeyer, Michael Hudecek, et al.
Blood|July 5, 2003
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivationMorgan Hakki, Stanley R Riddell, Jan Storek, et al.
The Journal of Experimental Medicine|March 18, 2009
Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupusZhenpeng Dai, Cameron J Turtle, Garrett C Booth, et al.
Cancer Journal (Sudbury, Mass.)|March 27, 2014
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset compositionStanley R Riddell, Daniel Sommermeyer, Carolina Berger, et al.
Pageof 18